# Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)

> **NCT02619630** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 275 (estimated)

## Conditions studied

- T-cell Adult Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** nelarabine

## Key facts

- **NCT ID:** NCT02619630
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2020-12
- **Final completion:** 2025-12
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2019-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02619630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02619630, "Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02619630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*